DUBLIN – Promethera Biosciences SA raised €39.7 million (US$44.4 million) in a series D funding round to progress clinical development of its lead cell therapy, Hepastem, in acute-on-chronic liver failure (ACLF) and nonalcoholic steatohepatitis (NASH), as well as to fund scale-up of its manufacturing capabilities and preclinical development of earlier-stage programs.